Immunosenescence

The age-associated decline in immune function across both adaptive (T and B lymphocyte) and innate (NK cell, neutrophil, macrophage) compartments. Not a clinical diagnosis — no standardized diagnostic criteria or ICD code exists. Immunosenescence is a research construct describing a multi-compartment process of immune remodeling that accompanies aging. Its consequences are real and clinically significant: increased susceptibility to infection, reduced vaccine efficacy, impaired cancer immune surveillance, and paradoxical contributions to autoimmunity — but the phenomenon resists reduction to any single biomarker or cutpoint.

Closely related to, but distinct from, inflammaging — the chronic low-grade sterile inflammation that also accumulates with age. The two processes co-occur and reinforce one another, but should be kept conceptually separate: immunosenescence is primarily about functional decline, whereas inflammaging is primarily about inflammatory tone¹.

Clinical and research definitions — no consensus criteria

Unlike sarcopenia (ICD-10 M62.84) or frailty (various scoring instruments), immunosenescence lacks a universally accepted operational definition or diagnostic algorithm. It is assessed indirectly via immune phenotyping, functional assays, and clinical endpoints.

The closest validated marker set is the Immune Risk Profile (IRP), derived from the Swedish OCTO and NONA longitudinal studies of very old adults (85–100 years old)². The IRP was originally defined by Wikby et al. 1998 (PMID 9720651, OCTO cohort) as a cluster of immune parameters predicting mortality over 2-year follow-up. The IRP comprises:

Inverted CD4:CD8 ratio — < 1.0 (normal > 1.5 in adults)
CMV seropositivity — CMV drives massive clonal CD8+ T cell expansion
Low B cell count in peripheral blood
Poor proliferative response to mitogens (originally defined by Wikby and colleagues)

IRP-positive individuals in the OCTO/NONA cohorts had substantially elevated 2-year mortality independent of other health status measures. This remains the most cited prognostic immune-aging signature, but has not been widely replicated with formal cutpoints in independent cohorts. needs-replication Note: the primary IRP papers (Wikby et al. 1998 and subsequent OCTO/NONA publications) are the canonical source; ² is a secondary review that synthesises this work. The cutpoints and exact mortality risk data should be verified against the Wikby primary papers.

Pathophysiology by compartment

Immunosenescence is not a single failure mode — it reflects parallel, interacting deterioration across every major immune compartment.

Thymic involution — the upstream driver

The thymus produces naive T cells from bone-marrow-derived progenitors. Involution begins at puberty and is near-complete by age 60 in most individuals, with the parenchyma replaced by adipose tissue². By age 70, thymic output of naive T cells is estimated to have fallen ~95% from young-adult levels. needs-human-replication (estimates vary widely; direct measurement is technically difficult) no-fulltext-access (cited source Nikolich-Žugich 2018 is not_oa; Goronzy & Weyand 2019, which is OA, states thymic contribution to T cell generation declines from ~16% to <1% over adult lifetime — a different framing; the 95% figure remains unverified against primary source)

Consequences:

The naive T cell pool shrinks and becomes dependent on homeostatic proliferation of existing cells rather than fresh thymic output
Naive T cell repertoire diversity contracts — reducing the breadth of antigens the adaptive immune system can recognise for the first time
New vaccines and novel pathogens are harder to mount primary responses against

T cell compartment — accumulation of senescent effectors

With age, the T cell compartment shifts from a diverse, naive-cell-rich pool toward an oligoclonally expanded, terminally differentiated memory pool³:

Loss of naive T cells (CD45RA+CCR7+): reduced thymic output + space increasingly occupied by memory cells
Expansion of TEMRA cells (terminally differentiated effector memory cells that have re-expressed CD45RA): CD95+, KLRG1+, CD57+, often CD28−; resist apoptosis, limited proliferative capacity, contribute to inflammaging via constitutive cytokine secretion
CD4:CD8 ratio inversion: in the very old (>85), inversion correlates with increased mortality (IRP component)
CMV-driven CD8+ clonal expansion: in CMV-seropositive individuals (~50–70% of adults), CMV-specific CD8+ T cells may constitute 10–50% of the entire CD8+ pool, crowding out other specificities — sometimes called “memory inflation” or “clonal exhaustion” of the repertoire² no-fulltext-access (Nikolich-Žugich 2018 is not_oa; this specific 10–50% range could not be verified against the primary source; Goronzy & Weyand 2019 discusses CMV memory inflation qualitatively but does not cite this percentage range)
Telomere attrition: repeated antigen-driven proliferation erodes T cell telomeres → telomere-attrition; CD8+ TEMRA cells have notably short telomeres and exhibit replicative senescence markers

Functional consequences: reduced IL-2 production, impaired activation-induced proliferation, reduced cytokine polyfunctionality, impaired help for B cells.

B cell compartment — reduced output and impaired response quality

Reduced B cell output from bone marrow with age (HSC myeloid bias affects lymphoid output — see stem-cell-exhaustion)
Naïve B cell pool contracts; repertoire diversity falls
Impaired class-switch recombination (CSR) and somatic hypermutation (SHM) — the processes that drive antibody affinity maturation and isotype selection
Reduced germinal centre reactions: smaller GC responses mean lower-avidity, lower-quantity antibody output to new antigens
Clinical implication: vaccine responses to novel antigens (influenza strains, COVID-19, herpes zoster) are substantially blunted in elderly. Seroprotection rates for standard influenza vaccine drop from ~70–90% in young adults to ~40–60% in adults over 65 needs-replication (rates vary substantially by vaccine platform, year, and population) no-fulltext-access (Nikolich-Žugich 2018 source is not_oa; figures are consistent with the literature but unverified against primary source)

NK cells — the “NK paradox”

Natural killer cells show a paradoxical pattern with age:

NK cell numbers increase in peripheral blood with age
Per-cell cytotoxicity decreases — each NK cell is functionally less effective
Shift toward mature CD56dim subsets; CD56bright (more cytokine-producing, less cytotoxic) subset relatively reduced
Reduced natural cytotoxicity receptors (NKp30, NKp46) — the most consistent activating-receptor change on aged NK cells ⁴. NKG2D on NK cells is comparatively preserved / inconsistent across studies; the robust NKG2D decline is on aged T cells (a frequent cell-type conflation). Increased inhibitory-receptor expression. See senescence-immune-surveillance for the reconciled receptor evidence and CMV confounding
Net effect: cancer immune surveillance is impaired despite numerically “normal” or elevated NK counts — the numbers mask functional exhaustion (direct per-cell cytotoxicity measurements with aging are inconsistently reported and partly CMV-confounded ⁵)

Innate immunity

Less studied than adaptive changes; generally shows reduced functional output:

Neutrophils: reduced chemotaxis toward infection sites; reduced NET (neutrophil extracellular trap) formation; impaired phagocytic killing per cell
Macrophages: reduced TLR signalling responsiveness (especially TLR1/2 and TLR7/8); altered M1/M2 polarisation balance; paradoxically, increased basal inflammatory tone (contributing to inflammaging)
Dendritic cells: reduced type I interferon production; impaired antigen presentation capacity; reduced migration to lymph nodes
Complement system: generally maintained but with altered regulation; mannan-binding lectin levels change with age unsourced

Inflammaging vs immunosenescence — a critical distinction

Feature	Immunosenescence	Inflammaging
Definition	Functional decline across immune compartments	Chronic, low-grade, sterile systemic inflammation
Key markers	CD4:CD8 ratio, naive T cell %, vaccine response	IL-6, CRP, TNF-α, IL-1β
Directionality	Immune responses too weak to novel antigens	Inflammatory tone too high at baseline
Relationship	Contributes to inflammaging (SASP-like TEMRA secretion); also damaged by it	Accelerates T cell senescence; sustains itself via NF-κB

The two phenomena overlap and reinforce one another: senescent T cells and macrophages secrete pro-inflammatory cytokines (contributing to inflammaging), while the chronic inflammatory milieu of inflammaging accelerates immune cell senescence and dysfunction¹. Understanding which is the upstream driver in any given individual remains an open question. contradictory-evidence

Drivers and accelerants

Driver	Mechanism
Age	All compartment changes are age-correlated; the strongest single factor
CMV seropositivity	Chronic latent CMV drives massive CD8+ TEMRA expansion (“inflationary” memory); accelerates all T cell aging features
Cellular senescence in immune cells	KLRG1+ CD57+ T cells are senescent; contribute SASP-like cytokines; resist clearance → cellular-senescence
Hematopoietic stem cell exhaustion	HSC myeloid bias reduces lymphoid progenitor output → fewer naive T and B cells → stem-cell-exhaustion
Telomere attrition	Proliferation-driven telomere erosion in T cells drives replicative senescence → telomere-attrition
Chronic antigen stimulation	CMV, CMV-associated antigens, latent viruses, and chronic infections maintain chronic activation
Inflammaging feedback	IL-6 and other inflammatory cytokines accelerate T cell differentiation toward effector/senescent states → chronic-inflammation
Thymic involution	Irreversible architecture loss; no new naive T cells to replace terminally differentiated pool
Malnutrition / micronutrient deficiency	Zinc, selenium, vitamin D deficiency impairs innate and adaptive immune function
Chronic stress / cortisol	HPA axis activation suppresses naive T cell maintenance; accelerates senescence phenotype
Sedentary lifestyle	Physical exercise has demonstrated anti-immunosenescence effects in observational data

Hallmark mapping

Immunosenescence is a convergent integrative phenotype driven by multiple hallmarks-of-aging:

stem-cell-exhaustion — HSC myeloid bias reduces lymphoid output; bone marrow niche aging impairs B cell development
cellular-senescence — senescent T cells (TEMRA, KLRG1+CD57+) accumulate and drive local and systemic SASP
chronic-inflammation — inflammaging and immunosenescence are mutually reinforcing; IL-6 and TNF-α accelerate T cell terminal differentiation
telomere-attrition — replicative T cell senescence is telomere-erosion dependent; CD8+ T cells in very old individuals have critically short telomeres

Clinical consequences

Vaccine response decline

The most practically important consequence. Elderly individuals generate weaker antibody responses to virtually all vaccines tested²:

Standard-dose influenza vaccine: seroprotection ~40–60% in 65+ vs ~70–90% in younger adults no-fulltext-access (Nikolich-Žugich 2018 not_oa; figure consistent with literature but unverified against primary source)
COVID-19 mRNA vaccines: antibody titres and T cell responses lower in older adults; wane faster
Shingles: Zostavax age-specific efficacy varies — ~38% in 70+ and ~70% in 60–69 are commonly cited figures from SPS subgroup analyses, but full-text subgroup confirmation not available here; Shingrix (subunit) achieved 89.8% efficacy in 70+ (ZOE-70 trial) needs-replication (Zostavax 70+ subgroup figure)

Increased infection mortality

Influenza, pneumococcal disease, herpes zoster, RSV — each disproportionately fatal in the elderly
COVID-19 age-mortality gradient is largely attributable to immunosenescence + inflammaging compound effects
Urinary tract infections, pneumonia — more frequent and more severe

Cancer immune surveillance failure

NK cell cytotoxicity decline and reduced CD8+ T cell naive diversity reduce surveillance of nascent tumours
T cell exhaustion in tumour microenvironments is exacerbated in elderly
Immune checkpoint immunotherapy response rates may differ by age (evidence mixed) contradictory-evidence

Paradoxical autoimmunity

Despite overall immune decline, rates of autoimmune phenomena paradoxically increase with age (rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis tend to occur in older adults). Proposed mechanism: loss of regulatory T cell (Treg) control; chronic inflammatory milieu drives autoreactive clones. no-mechanism

Interventions

Vaccine formulation strategies (approved/in-use)

The most established clinical approach to immunosenescence is circumventing the weakened vaccine response rather than reversing immune decline:

Vaccine	Strategy	Evidence
Fluzone High-Dose (influenza)	4× standard antigen dose; overcomes reduced B cell response	24.2% relative efficacy advantage vs standard dose in 65+ (95% CI 9.7–36.5; DiazGranados et al. 2014 NEJM, n=31,989, phase IIIb-IV RCT; PMID 25119609)
Fluad (influenza + MF59 adjuvant)	Adjuvant amplifies innate immune signal; increases GC response	Superior seroconversion in elderly; approved for 65+
Shingrix (herpes zoster, AS01B adjuvant)	Potent AS01B (MPL + QS-21) adjuvant; subunit vaccine	89.8% efficacy in 70+ (ZOE-70 trial, n=13,900; 95% CI 84.2–93.7) vs ~51% overall for live-attenuated Zostavax (SPS trial); Zostavax age-specific figure for 70+ unverified — commonly cited as ~38% but full-text SPS subgroup data not confirmed here needs-replication

mTOR inhibition — first geroprotector trial in humans

Mannick et al. 2014 (RAD001 / everolimus, a rapalogue) in healthy elderly volunteers: RAD001 enhanced the influenza vaccine response by ~20% at well-tolerated doses, and reduced the percentage of CD4 and CD8 T lymphocytes expressing PD-1 (programmed death-1 receptor), which is more highly expressed with age and inhibits T cell signalling⁶. Note: the paper describes PD-1 (the receptor on T cells), not PD-L1 (the ligand). This was the first prospective RCT to demonstrate that a geroprotector compound can improve immune function in aged humans. The n=218 figure cited in the footnote below is not present in the published abstract; it would require full-text access to confirm. needs-replication See mtor for broader context.

Dimension	Status
Pathway conserved in humans?	Yes — mTORC1 signalling controls T cell differentiation in humans
Phenotype conserved in humans?	Yes — trial conducted in humans
Replicated in humans?	In-progress — PEARL trial ongoing; single positive trial

Senolytics — preclinical and emerging

Clearance of senescent immune cells (particularly TEMRA/KLRG1+CD57+ cells) may partially restore immune function. Evidence is largely preclinical:

fisetin and dasatinib + quercetin clear senescent cells in mouse models; immune compartment effects in aging are not yet well characterized in humans needs-human-replication
Fisetin human trials ongoing (NCT03430037 and related); immune-specific endpoints not primary in published reports to date

Thymic regeneration (preclinical)

Multiple approaches investigated to restore thymic output:

IL-7 — cytokine supporting naive T cell homeostasis; modest expansion of naive T cell pool in trials; thymic output itself not clearly restored
KGF (keratinocyte growth factor / palifermin) — thymic epithelial cell support; studied post-BMT; limited direct anti-immunosenescence evidence
Sex steroid blockade (e.g., LHRH agonists + aromatase inhibitors) — reduces androgen-mediated thymic suppression; modest transient increases in thymic output in small trials; not practical at population scale
FOXN1 gene therapy — transcription factor essential for thymic epithelium; preclinical-only; early mouse data promising needs-human-replication

CMV vaccine / CMV control

Eliminating the primary driver of CD8+ repertoire collapse (CMV latent infection) would logically slow a major immunosenescence mechanism. No approved CMV vaccine exists as of 2026. Multiple vaccine candidates in Phase 2–3 trials. long-term-unknown

Lifestyle

Aerobic + resistance exercise — robust observational evidence for attenuated immunosenescence in physically active elderly; some interventional evidence. Mechanisms include reduced inflammation, improved NK cell function, partial TEMRA expansion delay. needs-replication for causal claims
Adequate nutrition — zinc and selenium replenishment in deficient elderly restores some innate immune parameters; not effective in replete individuals
Caloric restriction — reduces inflammatory markers in humans (CALERIE trial); direct immune-aging effects in humans not well characterized

Risk factors

Factor	Evidence level
Age	Strongest predictor; continuous dose-response
CMV seropositivity	Strong; major modifier of T cell aging trajectory
Chronic disease burden	Moderate; chronic inflammation accelerates immune aging
Sedentary lifestyle	Moderate (mostly observational)
Malnutrition / micronutrient deficiency	Moderate; well-established for specific deficiencies (zinc)
Chronic psychological stress	Moderate (mostly observational); HPA-immune axis
Sex (male)	Modest; men have slightly higher CMV-driven TEMRA accumulation in some cohorts contradictory-evidence

Limitations and gaps

No diagnostic criteria: The absence of a standardised operational definition makes prevalence estimates and intervention trials difficult to compare across studies. Any “reversal of immunosenescence” claim requires careful specification of what was measured. needs-replication
IRP validation gap: The Immune Risk Profile has compelling prognostic data in Scandinavian very-old cohorts but limited independent external validation with strict cutpoints.
Causation vs correlation: Most immune phenotyping is cross-sectional; longitudinal data is limited. Which immune changes drive adverse outcomes vs. which are epiphenomena is largely unknown for most compartments.
CMV confound: CMV seropositivity is a major modifier of the immune aging phenotype. Studies that don’t stratify by CMV status may be mixing two very different immunological aging trajectories.
NK cell paradox mechanism: Why NK cell numbers increase while per-cell function decreases is not mechanistically resolved. no-mechanism
Mouse models: Inbred mouse strains used in most immunosenescence experiments are CMV-naive; they miss the major CMV-driven remodeling central to human immunosenescence. Extrapolation from mouse models is particularly limited here.

Sex differences in immune aging

Sex is one of the strongest biological modifiers of immune function across the lifespan, and its effects persist into — and interact with — age-related immune decline.

Baseline sex asymmetry

Females consistently mount stronger innate and adaptive immune responses than males: higher antibody titres after vaccination, faster viral clearance, and greater B and T cell responses to novel antigens⁷. This pattern holds across virtually all vaccine types studied and across diverse infectious challenges. The cost of heightened immune reactivity is a substantially elevated autoimmunity burden: approximately 80% of autoimmune-disease patients are female, a proportion widely attributed to sex-biased immune tone rather than sex-specific exposures⁷. no-mechanism (the causal link between vaccine-response advantage and autoimmunity susceptibility is incompletely resolved; shared upstream regulators are proposed but not established)

Mechanistic contributors

Two categories of mechanism are currently best supported:

X-linked immune gene dosage. Several immune-regulatory genes reside on the X chromosome and escape complete X-chromosome inactivation in female cells, resulting in higher effective dosage in females. Key examples include TLR7 (a pattern-recognition receptor sensing single-stranded RNA, linked to type I interferon amplification) and CD40LG (CD154, a T cell costimulatory ligand). x-chromosome-inactivation covers the TLR7 escape mechanism in detail, including the Dou 2024 XIST-autoimmunity data. Incomplete X-inactivation is now recognised as a quantitative variable — not a binary on/off — and its contribution to immune sex differences in older age (when global epigenetic erosion accelerates) is an active research area. needs-replication

Gonadal hormone immunomodulation. estradiol is broadly immune-enhancing: estrogen-response elements are present in promoters of cytokine and immunoglobulin genes; estrogen signalling promotes B cell class-switching, dendritic cell activation, and type I interferon production. testosterone is broadly immunosuppressive at physiological concentrations, dampening inflammatory responses, reducing antibody production, and shifting macrophages toward anti-inflammatory polarisation. These hormonal effects are quantitatively important in reproductive-age adults; their contribution to post-menopausal and post-andropause immune aging is less well characterised. needs-human-replication

Aging trajectory divergence

The two sexes do not simply start from different immune baselines and decline in parallel — the rates and compartments of immune aging diverge with age. Márquez et al. 2020 (Nature Communications, n=172, ATAC-seq + RNA-seq + flow cytometry across ages 22–93) found that while both sexes share a core epigenomic aging signature (declining naive T cell and increasing monocyte/cytotoxic cell gene programs), the magnitude of age-related epigenomic change is greater in men⁸. After age 65, men showed higher innate and pro-inflammatory activity and lower adaptive immune activity relative to women. The study also identified two distinct aging “spikes” — an early-middle-age transition (around late-thirties/early-forties) affecting both sexes with similar timing and magnitude, and a second spike that is earlier (ages 62–64 in men vs 66–71 in women) and stronger in men⁸. A male-specific decline in B-cell-specific chromatin loci was also observed. The net picture is that men, despite lower baseline immune reactivity at younger ages, accrue signs of inflammaging-type immune remodeling at a faster rate in later life. contradictory-evidence (not all compartments or study populations show the same directional pattern; CMV-stratification and hormonal status confound cross-sectional comparisons)

Longevity connection and autoimmunity trade-off

The female immune advantage in responding to pathogens and vaccines is a plausible contributor to the female longevity advantage — see female-longevity-advantage for the broader evidence base. The autoimmunity trade-off (higher female autoimmune burden but longer female lifespan) suggests the immune-robustness hypothesis is one of several competing evolutionary pressures, not a clean net-positive story. From an aging-intervention perspective, sex-stratified analysis is essential: interventions targeting immune function (mTOR inhibition, senolytics, vaccine formulations) may have different efficacy profiles in men and women, but few aging-immune trials have been adequately powered for sex-subgroup analysis. needs-replication

Footnotes

doi:10.1093/gerona/glu057 · Franceschi C, Campisi J (2014) “Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases” · J Gerontology Series A · review · cited by ~3600 · foundational inflammaging concept paper ↩ ↩²
doi:10.1038/s41590-017-0006-x · Nikolich-Žugich J (2018) “The twilight of immunity: emerging concepts in aging of the immune system” · Nature Immunology · review · cited by ~995 (Crossref as of 2026-04-29) · comprehensive cross-compartment immunosenescence review · not_oa: quantitative claims attributed to this source (thymic output ~95%, CMV CD8+ 10–50%, influenza seroprotection 40–60% in 65+) could not be verified against the full text no-fulltext-access ↩ ↩² ↩³ ↩⁴ ↩⁵
doi:10.1038/s41577-019-0180-1 · Goronzy JJ, Weyand CM (2019) “Mechanisms underlying T cell ageing” · Nature Reviews Immunology · review · cited by ~456 (OpenAlex) · OA status: green (PMC7584388) but PDF download failed in a local paper archive · Verified via PMC full text: thymic contribution to T cell generation declines from ~16% to <1% over adult lifetime; T cell memory to CMV tends to inflate qualitatively — specific 10–50% CMV CD8+ range and influenza seroprotection figures are NOT stated in this paper ↩
doi:10.1016/j.humimm.2011.01.009 · Almeida-Oliveira A et al. · Hum Immunol 2011 Apr;72(4):319-29 · observational (flow cytometry, healthy donors childhood→old age) · NK cells: NKp30 + NKp46 (NCRs) decreased in elderly; NKG2D decreased on T cells, NOT NK cells of elderly subjects · PMID 21262312 · abstract directly read 2026-05-31; full PDF not retrieved needs-fulltext-verification · canonical reconciliation on senescence-immune-surveillance ↩
doi:10.1016/j.exger.2014.01.008 · Campos C, Pera A, Sanchez-Correa B et al. · Exp Gerontol 2014 Jun;54:130-7 · observational (CMV-stratified) · CD57⁺/NKG2C⁺ NK expansion tracks CMV seropositivity rather than chronological age; age and CMV have separable effects on NK subsets · PMID 24440462 · not_oa; abstract-level 2026-05-31 no-fulltext-access ↩
doi:10.1126/scitranslmed.3009892 · Mannick JB et al. (2014) “mTOR inhibition improves immune function in the elderly” · Science Translational Medicine · rct · n=unconfirmed from abstract (n=218 is widely cited but not stated in published abstract — full text is closed-access) · randomized · ~20% improvement in influenza vaccine response; reduced PD-1 (not PD-L1) expression on CD4 and CD8 T cells · model: elderly human volunteers (also cited in mtor) ↩
doi:10.1038/nri.2016.90 · Klein SL, Flanagan KL (2016) “Sex differences in immune responses” · Nature Reviews Immunology 16(10):626–638 · review · PMID 27546235 · cited by >1000 · comprehensive cross-compartment synthesis of sex-biased immune function; covers X-linked gene dosage (TLR7, CD40LG), sex hormone immunomodulation, vaccine-response sex differences, and autoimmunity burden · not_oa; claims attributed to this source are abstract/review-level; quantitative figures should be verified against primary sources cited therein no-fulltext-access ↩ ↩²
doi:10.1038/s41467-020-14396-9 · Márquez EJ, Chung C-H, Marches R et al. (2020) “Sexual-dimorphism in human immune system aging” · Nature Communications 11:751 · observational (ATAC-seq + RNA-seq + flow cytometry; n=172 donors ages 22–93; 91 women, 81 men; PMBCs from community-dwelling healthy adults) · PMID 32029736 · cited by ~488 · key findings: shared epigenomic aging signature (declining naive T, rising monocyte/cytotoxic programs); greater magnitude of age-related epigenomic change in men; male-specific decline in B-cell-specific loci; two aging “spikes” at late-thirties/early-forties (similar between sexes) and ages 62–64 in men / 66–71 in women (second spike earlier and stronger in men); post-65 men show higher innate/pro-inflammatory and lower adaptive activity vs women · OA (Nature Communications); full text verified 2026-06-03 against local PDF ↩ ↩²

🧬 Aging Wiki

Explorer

immunosenescence